多烯紫杉醇免疫脂质体对Lovo细胞的靶向放射增敏研究
摘要
研究背景:
多烯紫杉醇是一种半化学合成的紫杉醇,它可促进微管聚集,稳定微管结构,阻止微管解聚。多烯紫杉醇为细胞周期特异的药物,并由此发挥放射增敏作用。但因选择性较差,对正常组织的毒副作用限制其应用范围。脂质体作为药物的载体可以提高药物的治疗指数,但脂质体本身无特异靶向性,在脂质双分子层中掺入对特异细胞具有选择性和亲合性的配体,利用细胞对配体的识别可得到专一性作用于靶细胞的靶向脂质体。将天然或修饰的抗体分子偶联到含有适当功能基团的脂质体上,形成免疫脂质体。作为药物载体具有独特的优点,目前它已应用于临床,并取得满意的效果。放射治疗是结直肠癌治疗的重要手段之一,然而结直肠癌为相对放射抗拒的肿瘤。常规的放射增敏剂由于选择性较差,对正常组织毒副作用限制了其应用范围。通过肿瘤特异性抗原抗体对增敏剂的靶向作用,可增加放射增敏的选择性。CEA一种位于肿瘤细胞膜上的肿瘤相关抗原,在大肠癌中表达最强,LoVo细胞为表达CEA的人结肠腺癌细胞株。
研究目的:
本研究采用一种将特异性CEA抗体粘附于与多烯紫杉醇脂质体相连的PEG末端的新方法,制备空间稳定免疫脂质体,提高其对靶向组织的选择性。降低对正常组织的非特异毒性反应;在研制的多烯紫杉醇免疫脂质体新剂型基础上,评价其对LoVo细胞的放射增敏作用,放射敏感性与肿瘤细胞的凋亡倾向及细胞周期的的关系。观察其对细胞凋亡相关蛋白表达的影响。为多烯紫杉醇免疫脂质体放射增敏作用的应用提供实验依据。
BacgroundDocetaxel is a semisynthetic taxane that affects polymerized tubulin both topromote microtubule formation and to inhibit its disassembly. Docetaxel is a phase-specific agent that may offer the potential for enhancement of radiosensitization. As the poor targeted, the toxities to the normal tissues limit the extents of application. Liposomes can enhance the therapeutic expontent as the carries of druges, but it has no targeted. Colorectal cancer is one of the most common malignant diseases in the world. In the treatment of colorectal cancer, local recurrence is a major problem. To improve overall survival and reduce local recurrence rate after surgery, additional radiotherapy was given either preoperatively or postoperatively.In order to enhance its beneficial radiosensitizing capability, docetaxel was incorporated into liposomes with antibody conjugate for the targeted delivery to specifical cancer cells. Combination sterical stabilization with targetability, docetaxel immunoliposomes were prepared. In this study, we attempt to investigate the radiosensitization of colon carcinomas targeting with docetaxel liposome conjugated to antibody specific for carcinoembryonic antigen (CEA). The aim of this study is selective delivery of docetaxel and enhancing the radiation sensitivity on human colon cancer cell. In order to increase radiotherapy effects of local tumor and to improve both the quality of life and overall survival, radiosensitizer should be targeted to deliver into the tumor and limited to normal tissue. This workshop
considered a new approach by use targeted radiosensitizer to improve radiotherapy. MethodsPreparation of immunoliposomal docetaxel: A new PEG-PE derivative that had been endgroup-functionalized with cyanuric chloride was first synthesized. Anti-carcinoembryonic antigen (CEA) monoclonal antibody can simply be coupled to this membrane anchor in mild basic conditions (pH 8.8) without the need for previous antibody derivatizations. The entrapment efficiency and the quality of prepared docetaxel immunoliposomes were evaluated. In vitro cell association of docetaxel immunoliposomes binding was determined. The function and activity of the coupling anti-CEA monoclonal antibody was also analyzed.Enhancement of radiosensitivity by immunoliposomal docetaxel in human colon adenocarcinoma LoVo cell: The optimal combination of immunoliposomal docetaxel and radiation in vitro was obtained by the cytotoxicity evaluation of immunoliposomal docetaxel and a single radiation treatment in human colon adenocarcinoma cell lines.The effect of immunoliposomal docetaxel in combination with radiation on the expression of apoptosis-related proteins and EGFR : The expression of apoptosis-associated proteins p53, Bcl-2 and Bax were detected by flow cytometry in LoVo cells. Fas -. FasL and survivin proteins were detected by immunohistochemical staining and were quantified using semi-quantitative analysis by image analysis system. Epidermal growth factor receptor (EGFR) was detected with Western blot. Carcinoembryonic antigen expressed in cell cultures was assessed by Sandwhich ELISA. ResultsThe mean particle size of docetaxel immunoliposomes was 213±17.4 nm. Encapsulation efficiency of docetaxel immunoliposomes was 97.6 %. Using flow cytometry to analyze the targetability of docetaxel immunoliposomes show a higher degree of in vitro cell binding compared to conventional docetaxel liposomes. Enzyme-linked immunosorbent assay (EILSA) indicated that the immunoreactivity of
antibodies on liposome was retained completely. A stable and selective targeted agent has been achieved by biophysical evaluation of docetaxel immunoliposomes. The MTT assay indicated the cellular growth inhibitory rates were dose-response and time- response. HT29 cells shown a strong cytotoxicity to immunoliposomal docetaxel compared with LoVo cells. Both cell lines showed a dose-response to a single radiation shot. The combined treatment LoVo cells were tested by clonogenic assay. 2nM, lOOnM immunoliposomal docetaxel enhanced radiosensitivity ( SERDo. SERoq were 1.70, 1.78 and 1.47, 1.63 respectivly), but 2nM liposomal docetaxel was less radiosensitive ( SERdo, SERoq werel.02, 1.03). Flow cytometric analysis showed the concomitant effect of 2nM docetaxel with 2Gy radiation exposure, significantly increased the percentage of G2-M cells and induced apoptosis (P O.01), by comparison with non-targeted docetaxel. TUNEL staining cells revealed a condensed TUNEL-positive nucleus and reflected apoptotic cell death. Immunoliposomal docetaxel induced the numbers of TUNEL positive nuclei increased (43.6%), in contrast to liposomal docetaxel (17.7 %). Targeted docetaxel also increased the DNA ladder formation in the combined treatment LoVo cells. Morphological evidence of apoptotic cells could be distinguished under the fluorescence microscope after staining with Hochest 33342. Many nuclear fragments were observed in LoVo cells with docetaxel radiosensitization The Immunoliposomal docetaxel treated LoVo cells showed Bax increased, but no significant changes in the expression of p53 and bcl-2 proteins were observed. By the effect of docetaxel radiosensitization, FasN FasL in LoVo cells were expressed higher than LoVo cells with non-targeted docetaxel treatment (p<0.01). Combined with radiation, docetaxel could inhibit the expression of survivin. EGFR was down-regulated by Immunoliposomal docetaxel. After exposures of docetaxel and radiation , carcinoembryonic antigen was increased in the cell cultures. ConclusionA stable and selective targeted agent has been achieved by biophysical evaluation of docetaxel immunoliposomes. A stable and selective targeted agent has been
achieved by biophysical evaluation of docetaxel immunoliposomes. The immunoliposomal docetaxel is able to enhance the radiosensitivity in LoVo cell. The different pathways involved in promotion of apoptosis undergo docetaxel radiosensitization.
多烯紫杉醇是一种半化学合成的紫杉醇,它可促进微管聚集,稳定微管结构,阻止微管解聚。多烯紫杉醇为细胞周期特异的药物,并由此发挥放射增敏作用。但因选择性较差,对正常组织的毒副作用限制其应用范围。脂质体作为药物的载体可以提高药物的治疗指数,但脂质体本身无特异靶向性,在脂质双分子层中掺入对特异细胞具有选择性和亲合性的配体,利用细胞对配体的识别可得到专一性作用于靶细胞的靶向脂质体。将天然或修饰的抗体分子偶联到含有适当功能基团的脂质体上,形成免疫脂质体。作为药物载体具有独特的优点,目前它已应用于临床,并取得满意的效果。放射治疗是结直肠癌治疗的重要手段之一,然而结直肠癌为相对放射抗拒的肿瘤。常规的放射增敏剂由于选择性较差,对正常组织毒副作用限制了其应用范围。通过肿瘤特异性抗原抗体对增敏剂的靶向作用,可增加放射增敏的选择性。CEA一种位于肿瘤细胞膜上的肿瘤相关抗原,在大肠癌中表达最强,LoVo细胞为表达CEA的人结肠腺癌细胞株。
研究目的:
本研究采用一种将特异性CEA抗体粘附于与多烯紫杉醇脂质体相连的PEG末端的新方法,制备空间稳定免疫脂质体,提高其对靶向组织的选择性。降低对正常组织的非特异毒性反应;在研制的多烯紫杉醇免疫脂质体新剂型基础上,评价其对LoVo细胞的放射增敏作用,放射敏感性与肿瘤细胞的凋亡倾向及细胞周期的的关系。观察其对细胞凋亡相关蛋白表达的影响。为多烯紫杉醇免疫脂质体放射增敏作用的应用提供实验依据。
BacgroundDocetaxel is a semisynthetic taxane that affects polymerized tubulin both topromote microtubule formation and to inhibit its disassembly. Docetaxel is a phase-specific agent that may offer the potential for enhancement of radiosensitization. As the poor targeted, the toxities to the normal tissues limit the extents of application. Liposomes can enhance the therapeutic expontent as the carries of druges, but it has no targeted. Colorectal cancer is one of the most common malignant diseases in the world. In the treatment of colorectal cancer, local recurrence is a major problem. To improve overall survival and reduce local recurrence rate after surgery, additional radiotherapy was given either preoperatively or postoperatively.In order to enhance its beneficial radiosensitizing capability, docetaxel was incorporated into liposomes with antibody conjugate for the targeted delivery to specifical cancer cells. Combination sterical stabilization with targetability, docetaxel immunoliposomes were prepared. In this study, we attempt to investigate the radiosensitization of colon carcinomas targeting with docetaxel liposome conjugated to antibody specific for carcinoembryonic antigen (CEA). The aim of this study is selective delivery of docetaxel and enhancing the radiation sensitivity on human colon cancer cell. In order to increase radiotherapy effects of local tumor and to improve both the quality of life and overall survival, radiosensitizer should be targeted to deliver into the tumor and limited to normal tissue. This workshop
considered a new approach by use targeted radiosensitizer to improve radiotherapy. MethodsPreparation of immunoliposomal docetaxel: A new PEG-PE derivative that had been endgroup-functionalized with cyanuric chloride was first synthesized. Anti-carcinoembryonic antigen (CEA) monoclonal antibody can simply be coupled to this membrane anchor in mild basic conditions (pH 8.8) without the need for previous antibody derivatizations. The entrapment efficiency and the quality of prepared docetaxel immunoliposomes were evaluated. In vitro cell association of docetaxel immunoliposomes binding was determined. The function and activity of the coupling anti-CEA monoclonal antibody was also analyzed.Enhancement of radiosensitivity by immunoliposomal docetaxel in human colon adenocarcinoma LoVo cell: The optimal combination of immunoliposomal docetaxel and radiation in vitro was obtained by the cytotoxicity evaluation of immunoliposomal docetaxel and a single radiation treatment in human colon adenocarcinoma cell lines.The effect of immunoliposomal docetaxel in combination with radiation on the expression of apoptosis-related proteins and EGFR : The expression of apoptosis-associated proteins p53, Bcl-2 and Bax were detected by flow cytometry in LoVo cells. Fas -. FasL and survivin proteins were detected by immunohistochemical staining and were quantified using semi-quantitative analysis by image analysis system. Epidermal growth factor receptor (EGFR) was detected with Western blot. Carcinoembryonic antigen expressed in cell cultures was assessed by Sandwhich ELISA. ResultsThe mean particle size of docetaxel immunoliposomes was 213±17.4 nm. Encapsulation efficiency of docetaxel immunoliposomes was 97.6 %. Using flow cytometry to analyze the targetability of docetaxel immunoliposomes show a higher degree of in vitro cell binding compared to conventional docetaxel liposomes. Enzyme-linked immunosorbent assay (EILSA) indicated that the immunoreactivity of
antibodies on liposome was retained completely. A stable and selective targeted agent has been achieved by biophysical evaluation of docetaxel immunoliposomes. The MTT assay indicated the cellular growth inhibitory rates were dose-response and time- response. HT29 cells shown a strong cytotoxicity to immunoliposomal docetaxel compared with LoVo cells. Both cell lines showed a dose-response to a single radiation shot. The combined treatment LoVo cells were tested by clonogenic assay. 2nM, lOOnM immunoliposomal docetaxel enhanced radiosensitivity ( SERDo. SERoq were 1.70, 1.78 and 1.47, 1.63 respectivly), but 2nM liposomal docetaxel was less radiosensitive ( SERdo, SERoq werel.02, 1.03). Flow cytometric analysis showed the concomitant effect of 2nM docetaxel with 2Gy radiation exposure, significantly increased the percentage of G2-M cells and induced apoptosis (P O.01), by comparison with non-targeted docetaxel. TUNEL staining cells revealed a condensed TUNEL-positive nucleus and reflected apoptotic cell death. Immunoliposomal docetaxel induced the numbers of TUNEL positive nuclei increased (43.6%), in contrast to liposomal docetaxel (17.7 %). Targeted docetaxel also increased the DNA ladder formation in the combined treatment LoVo cells. Morphological evidence of apoptotic cells could be distinguished under the fluorescence microscope after staining with Hochest 33342. Many nuclear fragments were observed in LoVo cells with docetaxel radiosensitization The Immunoliposomal docetaxel treated LoVo cells showed Bax increased, but no significant changes in the expression of p53 and bcl-2 proteins were observed. By the effect of docetaxel radiosensitization, FasN FasL in LoVo cells were expressed higher than LoVo cells with non-targeted docetaxel treatment (p<0.01). Combined with radiation, docetaxel could inhibit the expression of survivin. EGFR was down-regulated by Immunoliposomal docetaxel. After exposures of docetaxel and radiation , carcinoembryonic antigen was increased in the cell cultures. ConclusionA stable and selective targeted agent has been achieved by biophysical evaluation of docetaxel immunoliposomes. A stable and selective targeted agent has been
achieved by biophysical evaluation of docetaxel immunoliposomes. The immunoliposomal docetaxel is able to enhance the radiosensitivity in LoVo cell. The different pathways involved in promotion of apoptosis undergo docetaxel radiosensitization.
引文
1. Spitz DR, Azzam EI, Li JJ, et al. Metabolic oxidation/reduction reactions and cellular responses to ionizing radiation: a unifying concept in stress response biology. Cancer Metastasis Rev 2004;23:311-322.
2. Valerie K, Dritschilo A, McKenna G, et al. Novel molecular targets for tumor radiosensitization: Molecular Radiation Biology and Oncology Workshop: translation of molecular mechanisms into clinical radiotherapy. Int J Cancer 2000;90:51-58.
3. Mitchell JB, Russo A, Cook JA, et al. Radiobiology and clinical application of halogenated pyrimidine radiosensitizers. Int J Radiat Biol 1989;56:827-836.
4. Dische S. A review of hypoxic cell radiosensitization. Int J Radiat Oncol Biol Phys 1991 ;20:147-152.
5. Murayama C, Mori T. Radiosensitization by hypoxic cell radiosensitizer present status of radiosensitizer. Gan No Rinsho 1990;36:2249-2254.
6. Martin LM, Thomas CD, Guichard M. Nicotinamide and carbogen: relationship between pO2 and radiosensitivity in three tumour lines. Int J Radiat Biol 1994;65:379-386.
7. Yamamoto F, Oka H, Antoku S, et al. Synthesis and characterization of lipophilic 1-[18F]fluoroalkyl-2-nitroimidazoles for imaging hypoxia. Biol Pharm Bull 1999;22:590-597.
8. Papadopoulou MV, Rosenzweig HS, Bloomer WD. Synthesis of a novel nitroimidazole-spermidine derivative as a tumor-targeted hypoxia-selective cytotoxin. Bioorg Med Chem Lett 2004; 14:1519-1522.
9. Janssens MY, Verovski VN, Van den Berge DL, et al. Radiosensitization of hypoxic tumour cells by S-nitroso-N-acetylpenicillamine implicates a bioreductive mechanism of nitric oxide generation. Br J Cancer 1999;79: 1085-1089.
10. Stern S, Guichard M. Efficacy of agents counteracting hypoxia in fractionated radiation regimes. Radiother Oncol 1996;41:143-149.
11. Koch CJ, Oprysko PR, Shuman AL, et al. Radiosensitization of hypoxic tumor cells by dodecafluoropentane: a gas-phase perfluorochemical emulsion. Cancer Res 2002;62:3626-3629.
12. Kozin SV, Hasegawa T, Kozina LV, et al. The use of a hypoxic cell radiosensitizer AK-2123 gave no improvement in thermoradiotherapy combined with hydralazine. Int J Hyperthermia 1996; 12:771-777.
13.Kasai S, Nagasawa H, Kuwasaka H, et al.TX-1877: design, synthesis, and biological activities as a BRM-functional hypoxic cell radiosensitizer. Int J Radiat Oncol Biol Phys 1998;42:799-802.
14. Naylor MA, Stephens MA, Stratford IJ, et al. Aziridinyl nitropyrroles and nitropyrazoles as hypoxia-selective cytotoxins and radiosensitizers. Anticancer Drug Des 1991;6:151-167.
15. Kohda Y. [Radiosensitization effect of new hypoxic cell radiosensitizer RK-27 on normal tissue and Ehrlich tumor of experimental animals]. Nippon Igaku Hoshasen Gakkai Zasshi 1988;48:497-508.
16. Kale RK. Exploitation of hypoxia for radiation therapy: a lesson from phenothiazines. Med Hypotheses 1996;47:107-110.
17. Koritzinsky M, Wouters BG, Amellem O, et al. Cell cycle progression and radiation survival following prolonged hypoxia and re-oxygenation. Int J Radiat Biol2001;77:319-328.
18. Van Buul PP, Van Duyn-Goedhart A, Beumer T, et al. Role of cell cycle control in radiosensitization of mouse spermatogonial stem cells. Int J Radiat Biol 2001;77:357-363.
19. Ree AH, Bratland A, Nome RV, et al. Inhibitory targeting of checkpoint kinase signaling overrides radiation-induced cell cycle gene regulation: a therapeutic strategy in tumor cell radiosensitization? Radiother Oncol 2004; 72:305-310.
20. Ostruszka LJ , Shewach DS. The role of cell cycle progression in radiosensitization by 2', 2'-difluoro-2'-deoxycytidine. Cancer Res 2000;60: 6080-6088.
21. McGinn CJ, Miller EM, Lindstrom MJ, et al. The role of cell cycle redistribution in radiosensitization: implications regarding the mechanism of fluorodeoxyuridine radiosensitization. Int J Radiat Oncol Biol Phys 1994;30: 851-859.
22. Kwok TT, Sutherland RM. Cell cycle dependence of epidermal growth factor induced radiosensitization. Int J Radiat Oncol Biol Phys 1992;22:525-527.
23. Pauwels B, Korst AE, Pattyn GG, et al. Cell cycle effect of gemcitabine and its role in the radiosensitizing mechanism in vitro. Int J Radiat Oncol Biol Phys 2003;57:1075-1083.
24. Geldof AA, Plaizier MA, Duivenvoorden I, et al. Cell cycle perturbations and radiosensitization effects in a human prostate cancer cell line. J Cancer Res Clin Oncol 2003;129:175-182.
25. Koritzinsky M, Wouters BG, Amellem O, et al. Cell cycle progression and radiation survival following prolonged hypoxia and re-oxygenation. Int J Radiat Biol 2001 ;77:319-328.
26. Chernikova SB, Lindquist KL, Elkind MM. Cell cycle-dependent effects of wortmannin on radiation survival and mutation. Radiat Res 2001;155:826-831
27. Gorodetsky R, Levdansky L, Ringel I, et al. Paclitaxel-induced modification of the effects of radiation and alterations in the cell cycle in normal and tumor mammalian cells. Radiat Res 1998; 150:283-291.
28. Naida JD, Davis MA, Lawrence TS. The effect of activation of wild-type p53 function on fluoropyrimidine-mediated radiosensitization. Int J Radiat Oncol Biol Phys 1998;41:675-680.
29. Chendil D, Oakes R, Alcock RA, et al. Low dose fractionated radiation enhances the radiosensitization effect of paclitaxel in colorectal tumor cells with mutant p53. Cancer 2000;89:1893-1900.
30. Bache M, Pigorsch S, Dunst J, et al. Loss of G2-M arrest correlates with radiosensitization in two human sarcoma cell lines with mutant p53. Int J Cancer 2001;96:110-117.
31. Zaugg K, Rocha S, Resch H, et al. Differential p53-dependent mechanism of radiosensitization in vitro and in vivo by the protein kinase C-specific inhibitor PKC412. Cancer Res 2001;61:732-738.
32. Powell SN, DeFrank JS, Connell P, et al. Differential sensitivity of p53(-) and p53(+) cells to caffeine-induced radiosensitization and override of G2 delay. Cancer Res 1995;55:1643-1648.
33. Zhang Z, Wang H, Prasad G, et al. Radiosensitization by antisense anti-MDM2 mixed-backbone oligonucleotide in in vitro and in vivo human cancer models. Clin Cancer Res 2004;10:1263-1273.
34. Axelson MD, Davis MA, Ethier SP, et al. HPV16-E7 expression causes fluorodeoxyuridine-mediated radiosensitization in SW620 human colon cancer cells. Neoplasia 1999;1:177-182.
35. Kawabe S, Roth JA, Wilson DR, et al. Adenovirus-mediated pl6INK4a gene expression radiosensitizes non-small cell lung cancer cells in a p53-dependent manner. Oncogene 2000; 19:5359-5366.
36. Muschel RJ, Soto DE, McKennaWG, et al. Radiosensitization and apoptosis. Oncogene 1998;17:3359-3363.
37. Kurdoglu B, Cheong N, Guan J, et al. Apoptosis as a predictor of paclitaxel-induced radiosensitization in human tumor cell lines. Clin Cancer Res 1999;5:2580-2587.
38. Grunbaum U, Meye A, Bache M, et al. Transfection with mdm2-antisense or wtp53 results in radiosensitization and an increased apoptosis of a soft tissue sarcoma cell line. Anticancer Res 2001 ;21:2065-2071.
39. Bracey TS, Williams AC, Paraskeva C. Inhibition of radiation-induced G2 delay potentiates cell death by apoptosis and/or the induction of giant cells in colorectal tumor cells with disrupted p53 function. Clin Cancer Res 1997;3:
1371-1381.
40. HiguchiK, Mitsuhashi N, Saitoh J, et al. Caffeine enhanced radiosensitivity of rat tumor cells with a mutant-type p53 by inducing apoptosis in a p53-independent manner. Cancer Lett 2000; 152:157-162.
41. Lawrence TS, Davis MA, Maybaum J, et al. The effect of single versus double-strand substitution on halogenated pyrimidine-induced radiosensitization and DNA strand breakage in human tumor cells. Radiat Res 1990; 123:192-198.
42. Olsson A, Sheng Y, Kjellen E, et al. In vivo tumor measurement of DNA damage, DNA repair and NAD pools as indicators of radiosensitization by metoclopramide. Carcinogenesis 1995;16:1029-1035.
43. Raaphorst GP, Yang DP, Ng CE. Comparison of survival and DNA double strand breaks for mild hyperthermia and low dose rate/pulsed low dose rate irradiation in human cells. J Therm Biol 2000;25:305-311.
44. Kunugi KA , Vazquez-Padua MA , Miller EM, et al. Modulation of IdUrd-DNA incorporation and radiosensitization in human bladder carcinoma cells. Cancer Res 1990;50:4962-4967.
45. Woudstra EC, Konings AW, Jeggo PA, et al. Role of DNA-PK subunits in radiosensitization by hyperthermia. Radiat Res 1999; 152:214-218.
46. Zeng ZC , Jiang GL , Wang GM , et al. DNA-PKcs subunits in radiosensitization by hyperthermia on hepatocellular carcinoma hepG2 cell line. World J Gastroenterol 2002;8:797-803.
47. Hashimoto M, Rao S, Tokuno O, et al. DNA-PK: the major target for wortmannin-mediated radiosensitization by the inhibition of DSB repair via NHEJ pathway. J Radiat Res (Tokyo) 2003;44:151-159.
48. Savitsky K, Sfez S, Tagle DA, et al. The complete sequence of the coding region of the ATM gene reveals similarity to cell cycle regulators in different species. Hum Mol Genet. 1995;4:2025-32.
49. Sarkaria JN, Busby EC, Tibbetts RS, et al. Inhibition of ATM and ATR kinase activities by the radiosensitizing agent, caffeine. Cancer Res 1999;59:
4375-4382.
50. Singh DR, Nair CK, Pradhan DS. Chemical radiosensitization by misonidazole: production and repair of DNA single-strand breaks in Yoshida ascites tumor cells. Indian J Exp Biol 1991;29:601-604.
51. Falk SJ, Smith PJ. DNA damaging and cell cycle effects of the topoisomerase I poison camptothecin in irradiated human cells. Int J Radiat Biol 1992;61:749-757.
52. Begemann M, Kashimawo SA, Heitjan DF, et al. Treatment of human glioblastoma cells with the staurosporine derivative CGP 41251 inhibits CDC2 and CDK2 kinase activity and increases radiation sensitivity. Anticancer Res 1998;18: 2275-2282.
53. Goldobenko GV, Matveev BP, Shipilov VI, , et al. Radiation treatment of bladder cancer using different fractionation regimens. Med Radiol. 1991;36:14-16.
54. Svensson H, Moller TR. Developments in radiotherapy. Acta Oncol. 2003; 42: 430-442.
55. Akudugu JM, Slabbert JP, Roos WP, et al. Micronucleus response of human glioblastoma and neuroblastoma cells toward low-LET photon and high-LET p(66)/Be neutron irradiation. Am J Clin Oncol. 2003 ;26: 1-6.
56. Kimura H. Usefulness of micronucleus assay in radiosensitivity tests using human cancer cell lines. Nippon Hinyokika Gakkai Zasshi. 1998;89:712-720.
57. Shibamoto Y, Streffer C, Sasai K, et al. Radiosensitization efficacy of KU-2285, RP-170 and etanidazole at low radiation doses: assessment by in vitro cytokinesis-block micronucleus assay. Int J Radiat Biol 1992;61:473-478.
58. Uma Devi P, Satish Rao BS, Kamath R. A method to score micronuclei in vivo using cytochalasin B-induced cytokinesis block. Mutat Res. 1998 5;401:33-337.
59. McGinn CJ, Kinsella TJ. The experimental and clinical rationale for the use of S-phase-specific radiosensitizers to overcome tumor cell repopulation. Semin Oncol 1992;19:21-28
60. Greenberg HS, Chandler WF, Diaz RF, et al. Intra-arterial 5-bromo-2-
deoxyuridine (BUdR) radiosensitization with external beam radiation in rhesus monkeys: toxicity study. JNeurooncol 1988;6:349-354.
61. Tsubouchi S, Kano E, Fukutsu K, et al. [Radiosensitization of mouse intestinal epithelial cells with BudR]. Gan No Rinsho 1990;36:2357-2361.
62. Yung WK. BUdR radiosensitization in anaplastic astrocytoma. Int J Radiat Oncol BiolPhys 1999;45:1105-1106.
63. Pignol JP, Rakovitch E, Beachey D, et al. Clinical significance of atomic inner shell ionization (ISI) and Auger cascade for radiosensitization using IUdR, BUdR, platinum salts, or gadolinium porphyrin compounds. Int J Radiat Oncol Biol Phys 2003;55:1082-1091.
64. Matsutani M, Kohno T, Nagashima T, et al. Clinical trial of intravenous infusion of bromodeoxyuridine (BUdR) for radiosensitization of malignant brain tumors. Radiat Med 1988;6:33-39.
65. Roy MB, Mandal PC, Bhattacharyya SN. Radiosensitization of thymine by copper(II) and nickel(II) complexes of metronidazole. Int J Radiat Biol 1996;69: 471-480.
66. Holden SA, Teicher BA, Herman TS. Effect of environmental conditions (pH, oxygenation , and temperature) on misonidazole cytotoxicity and radiosensitization in vitro and in vivo in FSaIIC fibrosarcoma. Int J Radiat Oncol Biol Phys 1991 ;20:1031-1038.
67. Stratford IJ, Adams GE, Godden J, et al. Induction of tumour hypoxia post-irradiation: a method for increasing the sensitizing efficiency of misonidazole and RSU 1069 in vivo. Int J Radiat Biol 1989;55:411-422.
68. DeGraff WG, Russo A, Friedman N, et al. Misonidazole hypoxic cytotoxicity and chemosensitization in two cell lines with different intracellular glutathione levels. Eur J Cancer 1990;26:17-20.
69. Wong KH , Maezawa H , Urano M. Comparative study of thermoradiosensitization by misonidazole and metronidazole in vivo: antitumour effect and pharmacokinetics. Int J Hyperthermia 1992;8:645-658.
70. Born JL, Smith BR, Harper N, et al. Metabolism and radiosensitization of 4, 5-dimethylmisonidazole, a ring-substituted analog of misonidazole. Biochem Pharmacol 1992;43:1337-1344.
71.Baillet F, Housset M, Dessard-Diana B, et al. Positive clinical experience with misonidazole in brachytherapy and external radiotherapy. Int J Radiat Oncol Biol Phys 1989;16:1073-1075.
72. Workman P. Accelerated elimination of pimonidazole following microsomal enzyme induction in mice: a possible approach to reduced neurotoxicity of the pimonidazole-etanidazole combination. Int J Radiat Oncol Biol Phys 1989;16:1011-1014.
73. Oya N, Shibamoto Y, Sasai K, et al. In vivo radiosensitization efficacy of KU-2285 and etanidazole at clinically relevant low radiation doses. Int J Radiat Oncol Biol Phys 1993;27:1113-1119.
74. Newman HF, Ward R, Workman P, et al. The multi-dose clinical tolerance and pharmacokinetics of the combined radiosensitizers, Ro 03-8799 (pimonidazole) and SR 2508 (etanidazole). Int J Radiat Oncol Biol Phys 1988;15:1073-1083.
75. Taghian A, Lespinasse F, Guichard ME. Radiosensitization by the combination of etanidazole (SR-2508) and pimonidazole (Ro 03-8799) in human tumor xenografts. Int J Radiat Oncol Biol Phys 1991 ;21:1535-1540.
76. Pasupathy K, Nair CK, Kagiya TV. Effect of a hypoxic radiosensitizer, AK2123 (Sanazole), on yeast Saccharomyces cerevisiae. J Radiat Res (Tokyo)2001;42:217-227.
77. Liu CX, Wei GL, Xiao SH. [Pharmacokinetics of sodium bimetrondazole glycinate in mice and rats. Yao Xue Xue Bao. 2000;35:770-773.
78. Henk JM, Bishop K, Shepherd SF. Treatment of head and neck cancer with CHART and nimorazole: phase II study. Radiother Oncol. 2003;66:65-70.
79. Brown JM, Siim BG. Hypoxia-Specific Cytotoxins in Cancer Therapy. Semin Radiat Oncol. 1996;6:22-36.
80.Naylor MA, Threadgill MD, Showalter HD, et al. Synthesis of the
enantiomers of the bioreductively-activated cytotoxin RSU-1069 and its prodrug RB6145 and lack of stereoselectivity in their cytotoxicity and radiosensitization in vitro. Drug Des Discov 1993;10:249-255.
81. Brown JM, Wang LH. Tirapazamine: laboratory data relevant to clinical activity. Anticancer Drug Des. 1998; 13:529-539.
82. Jounaidi Y, Waxman DJ. Combination of the bioreductive drug tirapazamine with the chemotherapeutic prodrug cyclophosphamide for P450/P450- reductase- based cancer gene therapy. Cancer Res. 2000;60:3761-2769.
83. Siim BG, Menke DR, Dorie MJ, et al. Tirapazamine-induced cytotoxicity and DNA damage in transplanted tumors: relationship to tumor hypoxia. Cancer Res. 1997; 57: 2922-2928.
84. RischinD, Peters L, Fisher R, et al. Tirapazamine, Cisplatin, and Radiation versus Fluorouracil, Cisplatin, and Radiation in patients with locally advanced head and neck cancer: a randomized phase II trial of the Trans-Tasman Radiation Oncology Group (TROG 98.02). J Clin Oncol. 2005;23:79-87.
85. Hicks KO, Fleming Y, Siim BG, et al. Extravascular diffusion of tirapazamine: effect of metabolic consumption assessed using the multicellular layer model. Int J Radiat Oncol Biol Phys. 1998;42:641-649.
86. Nakatsugawa S, Sugahara T. Inhibition of X-ray-induced potentially lethal damage (PLD) repair by cordycepin (3'-deoxyadenosine) and enhancement of its action by 2'-deoxycoformycin in Chinese hamster hai cells in the stationary phase in vitro. Radiat Res. 1980;84:265-275.
87. Nakatsugawa S, Sugahara T, Kumar A. Purine nucleoside analogues inhibit the repair of radiation-induced potentially lethal damage in mammalian cells in culture. Int J Radiat Biol Relat Stud Phys Chem Med. 1982;4:343-346.
88. Nakatsugawa S , Sugahara T. Effects of inhibitors of radiation-induced potentially lethal damage repair on chemotherapy in murine tumors. Int J Radiat Oncol Biol Phys. 1982;8:1555-1559.
89. Mirzayans R, Enns L, Cubitt S, et al. Effect of DNA polymerase inhibitors on
repair of gamma ray-induced DNA damage in proliferating (intact versus permeable) human fibroblasts: evidence for differences in the modes of action of aphidicolin and 1-beta-D-arabinofuranosylcytosine. Biochim Biophys Acta. 1994;1227:92-100.
90. McNally NJ, Soranson JA. Radiosensitization by misonidazole during recovery of cellular thiols following depletion by BSO or DEM. Int J Radiat Oncol Biol Phys 1989;16:1331-1334.
91. Yi X, Ding L, Jin Y, et al. The toxic effects, GSH depletion and radiosensitivity by BSO on retinoblastoma. Int J Radiat Oncol Biol Phys 1994;29:393-396.
92. Kramer RA, Soble M, Howes AE, et al. The effect of glutathione (GSH) depletion in vivo by buthionine sulfoximine (BSO) on the radiosensitization of SR 2508. Int J Radiat Oncol Biol Phys 1989;16:1325-1329.
93. Teicher BA, Rockwell S, Lee JB. Radiosensitization of EMT6 cells by four platinum complexes. Int J Radiat Oncol Biol Phys. 1985;:937-941.
94. Skov KA, Palcic B, Harrison IE, et al. Modification of the action of misonidazole. II. Effect of TAN on radiosensitization. Int J Radiat Biol Relat Stud Phys Chem Med. 1980;37:613-620.
95. Lagrange JL, Bondiau PY, Tessier E, et al. Tumoral platinum concentrations in patients treated with repeated low-dose cisplatin as a radiosensitizer. Int J Cancer 1996;68:452-456.
96. Flentje M, Eble M, Haner U, et al. Additive effects of cisplatin and radiation in human tumor cells under oxic conditions. Radiother Oncol 1992;24:60-63.
97. Raaphorst GP , Miao J , Ng CE. Cisplatin and mild hyperthermia in radiosensitization to low dose rate irradiation in human ovarian carcinoma cells. Anticancer Res 1997;17:3469-3472.
98. Wheeler RH, Spencer S. Cisplatin plus radiation therapy. J Infus Chemother. 1995;5:61-66.
99. Caney C, Singh G, Lukka H, et al. Combined gamma-irradiation and
subsequent cisplatin treatment in human squamous carcinoma cell lines sensitive and resistant to cisplatin. Int J Radiat Biol 2004;80:291-299.
100. Yang LX , Wang HJ , Holton RA. In vitro efficacy of a novel chemoradiopotentiator taxoltere metro. Int J Radiat Oncol Biol Phys 2000;46:159-163.
101. Liebmann J, Cook JA, Fisher J, et al. In vitro studies of Taxol as a radiation sensitizer in human tumor cells. J Natl Cancer Inst 1994;86:441-446.
102. Cordes N, Plasswilm L, Sauer R. Interaction of paclitaxel (Taxol) and irradiation. In-vitro differences between tumor and fibroblastic cells. Strahlenther Onkol 1999;175:175-181.
103. Lovey J, Koronczay K, Remenar E, et al. [Low-dose Taxol radiosensitization in locally advanced head and neck cancers]. Magy Onkol 2001;45:201-206.
104. Geard CR, Jones JM. Radiation and taxol effects on synchronized human cervical carcinoma cells. Int J Radiat Oncol Biol Phys 1994;29:565-569.
105. Rosenthal DI, Carbone DP. Taxol plus radiation for head and neck cancer. J Infus Chemother 1995;5:46-54.
106. Milas L, Hunter N, Mason KA, et al. Tumor reoxygenation as a mechanism of taxol-induced enhancement of tumor radioresponse. Acta Oncol 1995;34:409-412.
107. Fleckenstein K, Eble M, et al. Radiosensitizing potential of gemcitabine (2',2'-difluoro-2'-deoxycytidine) within the cell cycle in vitro. Int J Radiat Oncol Biol Phys 1998;41:875-882.
108. Lawrence TS, Davis MA, Hough A, et al. The role of apoptosis in 2', 2'-difluoro-2'-deoxycytidine (gemcitabine)-mediated radiosensitization. Clin Cancer Res 2001 ;7:314-319.
109. Wachters FM, van Putten JW, Maring JG, et al. Selective targeting of homologous DNA recombination repair by gemcitabine. Int J Radiat Oncol Biol Phys 2003;57:553-562.
110. Gregoire V, Beauduin M, Rosier JF, et al. Kinetics of mouse jejunum
radiosensitization by 2' , 2'-difiuorodeoxycytidine (gemcitabine) and its relationship with pharmacodynamics of DNA synthesis inhibition and cell cycle redistribution in crypt cells. Br J Cancer 1997;76:1315-1321.
111. Chen AY, Shih SJ, Garriques LN, et al. Silatecan DB-67 is a novel DNA topoisomerase I-targeted radiation sensitizer. Mol Cancer Ther 2005;4:317-324.
112. Chen AY, Choy H, Rothenberg ML. DNA topoisomerase I-targeting drugs as radiation sensitizers. Oncology (Hunting:) 1999; 13:39-46.
113. Chen AY. Chou R, Shih SJ, et al. Enhancement of radiotherapy with DNA topoisomerase I-targeted drugs. Crit Rev Oncol Hematol 2004;50:111-119.
114. Chen AY, Shih SJ, Hsiao M, et al. Induction of radiosensitization by indolocarbazole derivatives: the role of DNA topoisomerase I. Mol Pharmacol 2004;66:553-560.
115. Rosenzweig KE, Youmell MB, Palayoor ST, et al. Radiosensitization of human tumor cells by the phosphatidylinositoB-kinase inhibitors wortmannin and LY294002 correlates with inhibition of DNA-dependent protein kinase and prolonged G2-M delay. Clin Cancer Res 1997;3:1149-1156.
116. Ortiz T, Lopez S, Burguillos MA, et al. Radiosensitizer effect of wortmannin in radioresistant bladder tumoral cell lines. Int J Oncol 2004;24:169-175.
117. Tomita M, Suzuki N, Matsumoto Y, et al. Sensitization by wortmannin of heat- or X-ray induced cell death in cultured Chinese hamster V79 cells. J Radiat Res (Tokyo) 2000;41:93-102.
118. Okayasu R, Suetomi K, Ullrich RL. Wortmannin inhibits repair of DNA double-strand breaks in irradiated normal human cells. Radiat Res 1998;149:440-445.
119. Eley KW, Benedict SH, Chung TD, et al. The effects of pentoxifylline on the survival of human glioma cells with continuous and intermittent stereotactic radiosurgery irradiation. Int J Radiat Oncol Biol Phys 2002;54:542-550.
120. Lee I , Levitt SH , Song CW. Improved tumour oxygenation and radiosensitization by combination with nicotinamide and pentoxifylline. Int J
Radiat Biol 1993;64:237-244.
121. Sperduto PW, Song CW, Levitt SH. The in vitro radiosensitization of human glioblastoma with pentoxifylline. Am J Clin Oncol 1993; 16:407-411.
122. Zywietz F, Bohm L, Sagowski C, et al. Pentoxifylline enhances tumor oxygenation and radiosensitivity in rat rhabdomyosarcomas during continuous hyperfractionated irradiation. Strahlenther Onkol 2004;180:306-314.
123. Lee I, Biaglow JE, Lee J, et al. Physiological mechanisms of radiation sensitization by pentoxifylline. Anticancer Res 2000;20:4605-4609.
124. Strunz AM, Peschke P, Waldeck W, et al. Preferential radiosensitization in p53-mutated human tumour cell lines by pentoxifylline-mediated disruption of the G2-M checkpoint control. Int J Radiat Biol 2002;78:721-732.
125. Binder A, TheronT, Donninger H, et al. Radiosensitization and DNA repair inhibition by pentoxifylline in NIH3T3 p53 transfectants. Int J Radiat Biol2002;78:991-1000.
126. Russell KJ, WiensLW, Demers GW, et al. Preferential radiosensitization of G1 checkpoint-deficient cells by methylxanthines. Int J Radiat Oncol Biol Phys1996;36:1099-1106.
127. Wang H, Boecker W, Wang H, et al. Caffeine inhibits homology-directed repair of I-SceI-induced DNA double-strand breaks. Oncogene 2004;23:824-834.
128. Rosenberg E, Hawkins W, Holmes M, et al. Radiosensitization of human glioma cells in vitro and in vivo with acyclovir and mutant HSV-TK75 expressed from adenovirus. Int J Radiat Oncol Biol Phys 2002;52:831-836.
129. Valerie K, Hawkins W, FarnsworthJ, et al. Substantially improved in vivo radiosensitization of rat glioma with mutant HSV-TK and acyclovir. Cancer Gene Ther 2001;8:3-8.
130. Valerie K, Brust D, Farnsworth J, et al. Improved radiosensitization of rat glioma cells with adenovirus-expressed mutant herpes simplex virus-thymidine kinase in combination with acyclovir. Cancer Gene Ther 2000;7:879-884.
131. Kim SH, Kim JH, Kolozsvary A, et al. Preferential radiosensitization of 9L
glioma cells transduced with HSV-tk gene by acyclovir. J Neurooncol 1997;33:189-194.
132. Rogulski KR, Wing MS, Paielli DL, et al. Double suicide gene therapy augments the antitumor activity of a replication-competent lytic adenovirus through enhanced cytotoxicity and radiosensitization. Hum Gene Ther 2000; 11:67-76.
133. Rogulski KR, Zhang K, Kolozsvary A, et al. Pronounced antitumor effects and tumor radiosensitization of double suicide gene therapy. Clin Cancer Res 1997;3:2081-2088.
134. Rogulski KR, Kim JH, Kim SH, et al. Glioma cells transduced with an Escherichia coli CD/HSV-1 TK fusion gene exhibit enhanced metabolic suicide and radiosensitivity. Hum Gene Ther. 1997;8:73-885.
135. Blackburn RV, GaloforoSS, CorryPM, et al. Adenoviral-mediated transfer of a heat-inducible double suicide gene into prostate carcinoma cells. Cancer Res. 1998;58:1358-1362.
136. Han R. Highlight on the studies of anticancer drugs derived from plants in China. Stem Cells. 1994;12:53-63.
137. Chen YJ. Potential role of tetrandrine in cancer therapy. Acta Pharmacol Sin 2002;23:1102-1106.
138. Koukourakis MI, Bizakis JG, Skoulakis CE, et al. Combined irinotecan, docetaxel and conventionally fractionated radiotherapy in locally advanced head and neck cancer. A phase I dose escalation study. Anticancer Res 1999; 19: 2305-2309.
139. Choy H, MacRae R. Irinotecan and radiation in combined-modality therapy for solid tumors. Oncology (Huntingt) 2001 ;15:22-28.
140. Mitchell EP. Irinotecan in preoperative combined-modality therapy for locally advanced rectal cancer. Oncology (Huntingt) 2000;14:56-59.
141. Wachsberger P, Burd R, Dicker AP. R Improving tumor response to radiotherapy by targeting angiogenesis signaling pathways. Hematol Oncol Clin
North Am. 2004;18:1039-1057.
142. Dewhirst MW, Sim DA. Estimation of therapeutic gain in clinical trials involving hyperthermia and radiotherapy. Int J Hyperthermia. 1986;2:165-178.
143. Fowler JF. Eighth annual Juan del Regato lecture. Chemical modifiers of radiosensitivity theory and reality: a review. Int J Radiat Oncol Biol Phys.1985;11:665-674.
2. Valerie K, Dritschilo A, McKenna G, et al. Novel molecular targets for tumor radiosensitization: Molecular Radiation Biology and Oncology Workshop: translation of molecular mechanisms into clinical radiotherapy. Int J Cancer 2000;90:51-58.
3. Mitchell JB, Russo A, Cook JA, et al. Radiobiology and clinical application of halogenated pyrimidine radiosensitizers. Int J Radiat Biol 1989;56:827-836.
4. Dische S. A review of hypoxic cell radiosensitization. Int J Radiat Oncol Biol Phys 1991 ;20:147-152.
5. Murayama C, Mori T. Radiosensitization by hypoxic cell radiosensitizer present status of radiosensitizer. Gan No Rinsho 1990;36:2249-2254.
6. Martin LM, Thomas CD, Guichard M. Nicotinamide and carbogen: relationship between pO2 and radiosensitivity in three tumour lines. Int J Radiat Biol 1994;65:379-386.
7. Yamamoto F, Oka H, Antoku S, et al. Synthesis and characterization of lipophilic 1-[18F]fluoroalkyl-2-nitroimidazoles for imaging hypoxia. Biol Pharm Bull 1999;22:590-597.
8. Papadopoulou MV, Rosenzweig HS, Bloomer WD. Synthesis of a novel nitroimidazole-spermidine derivative as a tumor-targeted hypoxia-selective cytotoxin. Bioorg Med Chem Lett 2004; 14:1519-1522.
9. Janssens MY, Verovski VN, Van den Berge DL, et al. Radiosensitization of hypoxic tumour cells by S-nitroso-N-acetylpenicillamine implicates a bioreductive mechanism of nitric oxide generation. Br J Cancer 1999;79: 1085-1089.
10. Stern S, Guichard M. Efficacy of agents counteracting hypoxia in fractionated radiation regimes. Radiother Oncol 1996;41:143-149.
11. Koch CJ, Oprysko PR, Shuman AL, et al. Radiosensitization of hypoxic tumor cells by dodecafluoropentane: a gas-phase perfluorochemical emulsion. Cancer Res 2002;62:3626-3629.
12. Kozin SV, Hasegawa T, Kozina LV, et al. The use of a hypoxic cell radiosensitizer AK-2123 gave no improvement in thermoradiotherapy combined with hydralazine. Int J Hyperthermia 1996; 12:771-777.
13.Kasai S, Nagasawa H, Kuwasaka H, et al.TX-1877: design, synthesis, and biological activities as a BRM-functional hypoxic cell radiosensitizer. Int J Radiat Oncol Biol Phys 1998;42:799-802.
14. Naylor MA, Stephens MA, Stratford IJ, et al. Aziridinyl nitropyrroles and nitropyrazoles as hypoxia-selective cytotoxins and radiosensitizers. Anticancer Drug Des 1991;6:151-167.
15. Kohda Y. [Radiosensitization effect of new hypoxic cell radiosensitizer RK-27 on normal tissue and Ehrlich tumor of experimental animals]. Nippon Igaku Hoshasen Gakkai Zasshi 1988;48:497-508.
16. Kale RK. Exploitation of hypoxia for radiation therapy: a lesson from phenothiazines. Med Hypotheses 1996;47:107-110.
17. Koritzinsky M, Wouters BG, Amellem O, et al. Cell cycle progression and radiation survival following prolonged hypoxia and re-oxygenation. Int J Radiat Biol2001;77:319-328.
18. Van Buul PP, Van Duyn-Goedhart A, Beumer T, et al. Role of cell cycle control in radiosensitization of mouse spermatogonial stem cells. Int J Radiat Biol 2001;77:357-363.
19. Ree AH, Bratland A, Nome RV, et al. Inhibitory targeting of checkpoint kinase signaling overrides radiation-induced cell cycle gene regulation: a therapeutic strategy in tumor cell radiosensitization? Radiother Oncol 2004; 72:305-310.
20. Ostruszka LJ , Shewach DS. The role of cell cycle progression in radiosensitization by 2', 2'-difluoro-2'-deoxycytidine. Cancer Res 2000;60: 6080-6088.
21. McGinn CJ, Miller EM, Lindstrom MJ, et al. The role of cell cycle redistribution in radiosensitization: implications regarding the mechanism of fluorodeoxyuridine radiosensitization. Int J Radiat Oncol Biol Phys 1994;30: 851-859.
22. Kwok TT, Sutherland RM. Cell cycle dependence of epidermal growth factor induced radiosensitization. Int J Radiat Oncol Biol Phys 1992;22:525-527.
23. Pauwels B, Korst AE, Pattyn GG, et al. Cell cycle effect of gemcitabine and its role in the radiosensitizing mechanism in vitro. Int J Radiat Oncol Biol Phys 2003;57:1075-1083.
24. Geldof AA, Plaizier MA, Duivenvoorden I, et al. Cell cycle perturbations and radiosensitization effects in a human prostate cancer cell line. J Cancer Res Clin Oncol 2003;129:175-182.
25. Koritzinsky M, Wouters BG, Amellem O, et al. Cell cycle progression and radiation survival following prolonged hypoxia and re-oxygenation. Int J Radiat Biol 2001 ;77:319-328.
26. Chernikova SB, Lindquist KL, Elkind MM. Cell cycle-dependent effects of wortmannin on radiation survival and mutation. Radiat Res 2001;155:826-831
27. Gorodetsky R, Levdansky L, Ringel I, et al. Paclitaxel-induced modification of the effects of radiation and alterations in the cell cycle in normal and tumor mammalian cells. Radiat Res 1998; 150:283-291.
28. Naida JD, Davis MA, Lawrence TS. The effect of activation of wild-type p53 function on fluoropyrimidine-mediated radiosensitization. Int J Radiat Oncol Biol Phys 1998;41:675-680.
29. Chendil D, Oakes R, Alcock RA, et al. Low dose fractionated radiation enhances the radiosensitization effect of paclitaxel in colorectal tumor cells with mutant p53. Cancer 2000;89:1893-1900.
30. Bache M, Pigorsch S, Dunst J, et al. Loss of G2-M arrest correlates with radiosensitization in two human sarcoma cell lines with mutant p53. Int J Cancer 2001;96:110-117.
31. Zaugg K, Rocha S, Resch H, et al. Differential p53-dependent mechanism of radiosensitization in vitro and in vivo by the protein kinase C-specific inhibitor PKC412. Cancer Res 2001;61:732-738.
32. Powell SN, DeFrank JS, Connell P, et al. Differential sensitivity of p53(-) and p53(+) cells to caffeine-induced radiosensitization and override of G2 delay. Cancer Res 1995;55:1643-1648.
33. Zhang Z, Wang H, Prasad G, et al. Radiosensitization by antisense anti-MDM2 mixed-backbone oligonucleotide in in vitro and in vivo human cancer models. Clin Cancer Res 2004;10:1263-1273.
34. Axelson MD, Davis MA, Ethier SP, et al. HPV16-E7 expression causes fluorodeoxyuridine-mediated radiosensitization in SW620 human colon cancer cells. Neoplasia 1999;1:177-182.
35. Kawabe S, Roth JA, Wilson DR, et al. Adenovirus-mediated pl6INK4a gene expression radiosensitizes non-small cell lung cancer cells in a p53-dependent manner. Oncogene 2000; 19:5359-5366.
36. Muschel RJ, Soto DE, McKennaWG, et al. Radiosensitization and apoptosis. Oncogene 1998;17:3359-3363.
37. Kurdoglu B, Cheong N, Guan J, et al. Apoptosis as a predictor of paclitaxel-induced radiosensitization in human tumor cell lines. Clin Cancer Res 1999;5:2580-2587.
38. Grunbaum U, Meye A, Bache M, et al. Transfection with mdm2-antisense or wtp53 results in radiosensitization and an increased apoptosis of a soft tissue sarcoma cell line. Anticancer Res 2001 ;21:2065-2071.
39. Bracey TS, Williams AC, Paraskeva C. Inhibition of radiation-induced G2 delay potentiates cell death by apoptosis and/or the induction of giant cells in colorectal tumor cells with disrupted p53 function. Clin Cancer Res 1997;3:
1371-1381.
40. HiguchiK, Mitsuhashi N, Saitoh J, et al. Caffeine enhanced radiosensitivity of rat tumor cells with a mutant-type p53 by inducing apoptosis in a p53-independent manner. Cancer Lett 2000; 152:157-162.
41. Lawrence TS, Davis MA, Maybaum J, et al. The effect of single versus double-strand substitution on halogenated pyrimidine-induced radiosensitization and DNA strand breakage in human tumor cells. Radiat Res 1990; 123:192-198.
42. Olsson A, Sheng Y, Kjellen E, et al. In vivo tumor measurement of DNA damage, DNA repair and NAD pools as indicators of radiosensitization by metoclopramide. Carcinogenesis 1995;16:1029-1035.
43. Raaphorst GP, Yang DP, Ng CE. Comparison of survival and DNA double strand breaks for mild hyperthermia and low dose rate/pulsed low dose rate irradiation in human cells. J Therm Biol 2000;25:305-311.
44. Kunugi KA , Vazquez-Padua MA , Miller EM, et al. Modulation of IdUrd-DNA incorporation and radiosensitization in human bladder carcinoma cells. Cancer Res 1990;50:4962-4967.
45. Woudstra EC, Konings AW, Jeggo PA, et al. Role of DNA-PK subunits in radiosensitization by hyperthermia. Radiat Res 1999; 152:214-218.
46. Zeng ZC , Jiang GL , Wang GM , et al. DNA-PKcs subunits in radiosensitization by hyperthermia on hepatocellular carcinoma hepG2 cell line. World J Gastroenterol 2002;8:797-803.
47. Hashimoto M, Rao S, Tokuno O, et al. DNA-PK: the major target for wortmannin-mediated radiosensitization by the inhibition of DSB repair via NHEJ pathway. J Radiat Res (Tokyo) 2003;44:151-159.
48. Savitsky K, Sfez S, Tagle DA, et al. The complete sequence of the coding region of the ATM gene reveals similarity to cell cycle regulators in different species. Hum Mol Genet. 1995;4:2025-32.
49. Sarkaria JN, Busby EC, Tibbetts RS, et al. Inhibition of ATM and ATR kinase activities by the radiosensitizing agent, caffeine. Cancer Res 1999;59:
4375-4382.
50. Singh DR, Nair CK, Pradhan DS. Chemical radiosensitization by misonidazole: production and repair of DNA single-strand breaks in Yoshida ascites tumor cells. Indian J Exp Biol 1991;29:601-604.
51. Falk SJ, Smith PJ. DNA damaging and cell cycle effects of the topoisomerase I poison camptothecin in irradiated human cells. Int J Radiat Biol 1992;61:749-757.
52. Begemann M, Kashimawo SA, Heitjan DF, et al. Treatment of human glioblastoma cells with the staurosporine derivative CGP 41251 inhibits CDC2 and CDK2 kinase activity and increases radiation sensitivity. Anticancer Res 1998;18: 2275-2282.
53. Goldobenko GV, Matveev BP, Shipilov VI, , et al. Radiation treatment of bladder cancer using different fractionation regimens. Med Radiol. 1991;36:14-16.
54. Svensson H, Moller TR. Developments in radiotherapy. Acta Oncol. 2003; 42: 430-442.
55. Akudugu JM, Slabbert JP, Roos WP, et al. Micronucleus response of human glioblastoma and neuroblastoma cells toward low-LET photon and high-LET p(66)/Be neutron irradiation. Am J Clin Oncol. 2003 ;26: 1-6.
56. Kimura H. Usefulness of micronucleus assay in radiosensitivity tests using human cancer cell lines. Nippon Hinyokika Gakkai Zasshi. 1998;89:712-720.
57. Shibamoto Y, Streffer C, Sasai K, et al. Radiosensitization efficacy of KU-2285, RP-170 and etanidazole at low radiation doses: assessment by in vitro cytokinesis-block micronucleus assay. Int J Radiat Biol 1992;61:473-478.
58. Uma Devi P, Satish Rao BS, Kamath R. A method to score micronuclei in vivo using cytochalasin B-induced cytokinesis block. Mutat Res. 1998 5;401:33-337.
59. McGinn CJ, Kinsella TJ. The experimental and clinical rationale for the use of S-phase-specific radiosensitizers to overcome tumor cell repopulation. Semin Oncol 1992;19:21-28
60. Greenberg HS, Chandler WF, Diaz RF, et al. Intra-arterial 5-bromo-2-
deoxyuridine (BUdR) radiosensitization with external beam radiation in rhesus monkeys: toxicity study. JNeurooncol 1988;6:349-354.
61. Tsubouchi S, Kano E, Fukutsu K, et al. [Radiosensitization of mouse intestinal epithelial cells with BudR]. Gan No Rinsho 1990;36:2357-2361.
62. Yung WK. BUdR radiosensitization in anaplastic astrocytoma. Int J Radiat Oncol BiolPhys 1999;45:1105-1106.
63. Pignol JP, Rakovitch E, Beachey D, et al. Clinical significance of atomic inner shell ionization (ISI) and Auger cascade for radiosensitization using IUdR, BUdR, platinum salts, or gadolinium porphyrin compounds. Int J Radiat Oncol Biol Phys 2003;55:1082-1091.
64. Matsutani M, Kohno T, Nagashima T, et al. Clinical trial of intravenous infusion of bromodeoxyuridine (BUdR) for radiosensitization of malignant brain tumors. Radiat Med 1988;6:33-39.
65. Roy MB, Mandal PC, Bhattacharyya SN. Radiosensitization of thymine by copper(II) and nickel(II) complexes of metronidazole. Int J Radiat Biol 1996;69: 471-480.
66. Holden SA, Teicher BA, Herman TS. Effect of environmental conditions (pH, oxygenation , and temperature) on misonidazole cytotoxicity and radiosensitization in vitro and in vivo in FSaIIC fibrosarcoma. Int J Radiat Oncol Biol Phys 1991 ;20:1031-1038.
67. Stratford IJ, Adams GE, Godden J, et al. Induction of tumour hypoxia post-irradiation: a method for increasing the sensitizing efficiency of misonidazole and RSU 1069 in vivo. Int J Radiat Biol 1989;55:411-422.
68. DeGraff WG, Russo A, Friedman N, et al. Misonidazole hypoxic cytotoxicity and chemosensitization in two cell lines with different intracellular glutathione levels. Eur J Cancer 1990;26:17-20.
69. Wong KH , Maezawa H , Urano M. Comparative study of thermoradiosensitization by misonidazole and metronidazole in vivo: antitumour effect and pharmacokinetics. Int J Hyperthermia 1992;8:645-658.
70. Born JL, Smith BR, Harper N, et al. Metabolism and radiosensitization of 4, 5-dimethylmisonidazole, a ring-substituted analog of misonidazole. Biochem Pharmacol 1992;43:1337-1344.
71.Baillet F, Housset M, Dessard-Diana B, et al. Positive clinical experience with misonidazole in brachytherapy and external radiotherapy. Int J Radiat Oncol Biol Phys 1989;16:1073-1075.
72. Workman P. Accelerated elimination of pimonidazole following microsomal enzyme induction in mice: a possible approach to reduced neurotoxicity of the pimonidazole-etanidazole combination. Int J Radiat Oncol Biol Phys 1989;16:1011-1014.
73. Oya N, Shibamoto Y, Sasai K, et al. In vivo radiosensitization efficacy of KU-2285 and etanidazole at clinically relevant low radiation doses. Int J Radiat Oncol Biol Phys 1993;27:1113-1119.
74. Newman HF, Ward R, Workman P, et al. The multi-dose clinical tolerance and pharmacokinetics of the combined radiosensitizers, Ro 03-8799 (pimonidazole) and SR 2508 (etanidazole). Int J Radiat Oncol Biol Phys 1988;15:1073-1083.
75. Taghian A, Lespinasse F, Guichard ME. Radiosensitization by the combination of etanidazole (SR-2508) and pimonidazole (Ro 03-8799) in human tumor xenografts. Int J Radiat Oncol Biol Phys 1991 ;21:1535-1540.
76. Pasupathy K, Nair CK, Kagiya TV. Effect of a hypoxic radiosensitizer, AK2123 (Sanazole), on yeast Saccharomyces cerevisiae. J Radiat Res (Tokyo)2001;42:217-227.
77. Liu CX, Wei GL, Xiao SH. [Pharmacokinetics of sodium bimetrondazole glycinate in mice and rats. Yao Xue Xue Bao. 2000;35:770-773.
78. Henk JM, Bishop K, Shepherd SF. Treatment of head and neck cancer with CHART and nimorazole: phase II study. Radiother Oncol. 2003;66:65-70.
79. Brown JM, Siim BG. Hypoxia-Specific Cytotoxins in Cancer Therapy. Semin Radiat Oncol. 1996;6:22-36.
80.Naylor MA, Threadgill MD, Showalter HD, et al. Synthesis of the
enantiomers of the bioreductively-activated cytotoxin RSU-1069 and its prodrug RB6145 and lack of stereoselectivity in their cytotoxicity and radiosensitization in vitro. Drug Des Discov 1993;10:249-255.
81. Brown JM, Wang LH. Tirapazamine: laboratory data relevant to clinical activity. Anticancer Drug Des. 1998; 13:529-539.
82. Jounaidi Y, Waxman DJ. Combination of the bioreductive drug tirapazamine with the chemotherapeutic prodrug cyclophosphamide for P450/P450- reductase- based cancer gene therapy. Cancer Res. 2000;60:3761-2769.
83. Siim BG, Menke DR, Dorie MJ, et al. Tirapazamine-induced cytotoxicity and DNA damage in transplanted tumors: relationship to tumor hypoxia. Cancer Res. 1997; 57: 2922-2928.
84. RischinD, Peters L, Fisher R, et al. Tirapazamine, Cisplatin, and Radiation versus Fluorouracil, Cisplatin, and Radiation in patients with locally advanced head and neck cancer: a randomized phase II trial of the Trans-Tasman Radiation Oncology Group (TROG 98.02). J Clin Oncol. 2005;23:79-87.
85. Hicks KO, Fleming Y, Siim BG, et al. Extravascular diffusion of tirapazamine: effect of metabolic consumption assessed using the multicellular layer model. Int J Radiat Oncol Biol Phys. 1998;42:641-649.
86. Nakatsugawa S, Sugahara T. Inhibition of X-ray-induced potentially lethal damage (PLD) repair by cordycepin (3'-deoxyadenosine) and enhancement of its action by 2'-deoxycoformycin in Chinese hamster hai cells in the stationary phase in vitro. Radiat Res. 1980;84:265-275.
87. Nakatsugawa S, Sugahara T, Kumar A. Purine nucleoside analogues inhibit the repair of radiation-induced potentially lethal damage in mammalian cells in culture. Int J Radiat Biol Relat Stud Phys Chem Med. 1982;4:343-346.
88. Nakatsugawa S , Sugahara T. Effects of inhibitors of radiation-induced potentially lethal damage repair on chemotherapy in murine tumors. Int J Radiat Oncol Biol Phys. 1982;8:1555-1559.
89. Mirzayans R, Enns L, Cubitt S, et al. Effect of DNA polymerase inhibitors on
repair of gamma ray-induced DNA damage in proliferating (intact versus permeable) human fibroblasts: evidence for differences in the modes of action of aphidicolin and 1-beta-D-arabinofuranosylcytosine. Biochim Biophys Acta. 1994;1227:92-100.
90. McNally NJ, Soranson JA. Radiosensitization by misonidazole during recovery of cellular thiols following depletion by BSO or DEM. Int J Radiat Oncol Biol Phys 1989;16:1331-1334.
91. Yi X, Ding L, Jin Y, et al. The toxic effects, GSH depletion and radiosensitivity by BSO on retinoblastoma. Int J Radiat Oncol Biol Phys 1994;29:393-396.
92. Kramer RA, Soble M, Howes AE, et al. The effect of glutathione (GSH) depletion in vivo by buthionine sulfoximine (BSO) on the radiosensitization of SR 2508. Int J Radiat Oncol Biol Phys 1989;16:1325-1329.
93. Teicher BA, Rockwell S, Lee JB. Radiosensitization of EMT6 cells by four platinum complexes. Int J Radiat Oncol Biol Phys. 1985;:937-941.
94. Skov KA, Palcic B, Harrison IE, et al. Modification of the action of misonidazole. II. Effect of TAN on radiosensitization. Int J Radiat Biol Relat Stud Phys Chem Med. 1980;37:613-620.
95. Lagrange JL, Bondiau PY, Tessier E, et al. Tumoral platinum concentrations in patients treated with repeated low-dose cisplatin as a radiosensitizer. Int J Cancer 1996;68:452-456.
96. Flentje M, Eble M, Haner U, et al. Additive effects of cisplatin and radiation in human tumor cells under oxic conditions. Radiother Oncol 1992;24:60-63.
97. Raaphorst GP , Miao J , Ng CE. Cisplatin and mild hyperthermia in radiosensitization to low dose rate irradiation in human ovarian carcinoma cells. Anticancer Res 1997;17:3469-3472.
98. Wheeler RH, Spencer S. Cisplatin plus radiation therapy. J Infus Chemother. 1995;5:61-66.
99. Caney C, Singh G, Lukka H, et al. Combined gamma-irradiation and
subsequent cisplatin treatment in human squamous carcinoma cell lines sensitive and resistant to cisplatin. Int J Radiat Biol 2004;80:291-299.
100. Yang LX , Wang HJ , Holton RA. In vitro efficacy of a novel chemoradiopotentiator taxoltere metro. Int J Radiat Oncol Biol Phys 2000;46:159-163.
101. Liebmann J, Cook JA, Fisher J, et al. In vitro studies of Taxol as a radiation sensitizer in human tumor cells. J Natl Cancer Inst 1994;86:441-446.
102. Cordes N, Plasswilm L, Sauer R. Interaction of paclitaxel (Taxol) and irradiation. In-vitro differences between tumor and fibroblastic cells. Strahlenther Onkol 1999;175:175-181.
103. Lovey J, Koronczay K, Remenar E, et al. [Low-dose Taxol radiosensitization in locally advanced head and neck cancers]. Magy Onkol 2001;45:201-206.
104. Geard CR, Jones JM. Radiation and taxol effects on synchronized human cervical carcinoma cells. Int J Radiat Oncol Biol Phys 1994;29:565-569.
105. Rosenthal DI, Carbone DP. Taxol plus radiation for head and neck cancer. J Infus Chemother 1995;5:46-54.
106. Milas L, Hunter N, Mason KA, et al. Tumor reoxygenation as a mechanism of taxol-induced enhancement of tumor radioresponse. Acta Oncol 1995;34:409-412.
107. Fleckenstein K, Eble M, et al. Radiosensitizing potential of gemcitabine (2',2'-difluoro-2'-deoxycytidine) within the cell cycle in vitro. Int J Radiat Oncol Biol Phys 1998;41:875-882.
108. Lawrence TS, Davis MA, Hough A, et al. The role of apoptosis in 2', 2'-difluoro-2'-deoxycytidine (gemcitabine)-mediated radiosensitization. Clin Cancer Res 2001 ;7:314-319.
109. Wachters FM, van Putten JW, Maring JG, et al. Selective targeting of homologous DNA recombination repair by gemcitabine. Int J Radiat Oncol Biol Phys 2003;57:553-562.
110. Gregoire V, Beauduin M, Rosier JF, et al. Kinetics of mouse jejunum
radiosensitization by 2' , 2'-difiuorodeoxycytidine (gemcitabine) and its relationship with pharmacodynamics of DNA synthesis inhibition and cell cycle redistribution in crypt cells. Br J Cancer 1997;76:1315-1321.
111. Chen AY, Shih SJ, Garriques LN, et al. Silatecan DB-67 is a novel DNA topoisomerase I-targeted radiation sensitizer. Mol Cancer Ther 2005;4:317-324.
112. Chen AY, Choy H, Rothenberg ML. DNA topoisomerase I-targeting drugs as radiation sensitizers. Oncology (Hunting:) 1999; 13:39-46.
113. Chen AY. Chou R, Shih SJ, et al. Enhancement of radiotherapy with DNA topoisomerase I-targeted drugs. Crit Rev Oncol Hematol 2004;50:111-119.
114. Chen AY, Shih SJ, Hsiao M, et al. Induction of radiosensitization by indolocarbazole derivatives: the role of DNA topoisomerase I. Mol Pharmacol 2004;66:553-560.
115. Rosenzweig KE, Youmell MB, Palayoor ST, et al. Radiosensitization of human tumor cells by the phosphatidylinositoB-kinase inhibitors wortmannin and LY294002 correlates with inhibition of DNA-dependent protein kinase and prolonged G2-M delay. Clin Cancer Res 1997;3:1149-1156.
116. Ortiz T, Lopez S, Burguillos MA, et al. Radiosensitizer effect of wortmannin in radioresistant bladder tumoral cell lines. Int J Oncol 2004;24:169-175.
117. Tomita M, Suzuki N, Matsumoto Y, et al. Sensitization by wortmannin of heat- or X-ray induced cell death in cultured Chinese hamster V79 cells. J Radiat Res (Tokyo) 2000;41:93-102.
118. Okayasu R, Suetomi K, Ullrich RL. Wortmannin inhibits repair of DNA double-strand breaks in irradiated normal human cells. Radiat Res 1998;149:440-445.
119. Eley KW, Benedict SH, Chung TD, et al. The effects of pentoxifylline on the survival of human glioma cells with continuous and intermittent stereotactic radiosurgery irradiation. Int J Radiat Oncol Biol Phys 2002;54:542-550.
120. Lee I , Levitt SH , Song CW. Improved tumour oxygenation and radiosensitization by combination with nicotinamide and pentoxifylline. Int J
Radiat Biol 1993;64:237-244.
121. Sperduto PW, Song CW, Levitt SH. The in vitro radiosensitization of human glioblastoma with pentoxifylline. Am J Clin Oncol 1993; 16:407-411.
122. Zywietz F, Bohm L, Sagowski C, et al. Pentoxifylline enhances tumor oxygenation and radiosensitivity in rat rhabdomyosarcomas during continuous hyperfractionated irradiation. Strahlenther Onkol 2004;180:306-314.
123. Lee I, Biaglow JE, Lee J, et al. Physiological mechanisms of radiation sensitization by pentoxifylline. Anticancer Res 2000;20:4605-4609.
124. Strunz AM, Peschke P, Waldeck W, et al. Preferential radiosensitization in p53-mutated human tumour cell lines by pentoxifylline-mediated disruption of the G2-M checkpoint control. Int J Radiat Biol 2002;78:721-732.
125. Binder A, TheronT, Donninger H, et al. Radiosensitization and DNA repair inhibition by pentoxifylline in NIH3T3 p53 transfectants. Int J Radiat Biol2002;78:991-1000.
126. Russell KJ, WiensLW, Demers GW, et al. Preferential radiosensitization of G1 checkpoint-deficient cells by methylxanthines. Int J Radiat Oncol Biol Phys1996;36:1099-1106.
127. Wang H, Boecker W, Wang H, et al. Caffeine inhibits homology-directed repair of I-SceI-induced DNA double-strand breaks. Oncogene 2004;23:824-834.
128. Rosenberg E, Hawkins W, Holmes M, et al. Radiosensitization of human glioma cells in vitro and in vivo with acyclovir and mutant HSV-TK75 expressed from adenovirus. Int J Radiat Oncol Biol Phys 2002;52:831-836.
129. Valerie K, Hawkins W, FarnsworthJ, et al. Substantially improved in vivo radiosensitization of rat glioma with mutant HSV-TK and acyclovir. Cancer Gene Ther 2001;8:3-8.
130. Valerie K, Brust D, Farnsworth J, et al. Improved radiosensitization of rat glioma cells with adenovirus-expressed mutant herpes simplex virus-thymidine kinase in combination with acyclovir. Cancer Gene Ther 2000;7:879-884.
131. Kim SH, Kim JH, Kolozsvary A, et al. Preferential radiosensitization of 9L
glioma cells transduced with HSV-tk gene by acyclovir. J Neurooncol 1997;33:189-194.
132. Rogulski KR, Wing MS, Paielli DL, et al. Double suicide gene therapy augments the antitumor activity of a replication-competent lytic adenovirus through enhanced cytotoxicity and radiosensitization. Hum Gene Ther 2000; 11:67-76.
133. Rogulski KR, Zhang K, Kolozsvary A, et al. Pronounced antitumor effects and tumor radiosensitization of double suicide gene therapy. Clin Cancer Res 1997;3:2081-2088.
134. Rogulski KR, Kim JH, Kim SH, et al. Glioma cells transduced with an Escherichia coli CD/HSV-1 TK fusion gene exhibit enhanced metabolic suicide and radiosensitivity. Hum Gene Ther. 1997;8:73-885.
135. Blackburn RV, GaloforoSS, CorryPM, et al. Adenoviral-mediated transfer of a heat-inducible double suicide gene into prostate carcinoma cells. Cancer Res. 1998;58:1358-1362.
136. Han R. Highlight on the studies of anticancer drugs derived from plants in China. Stem Cells. 1994;12:53-63.
137. Chen YJ. Potential role of tetrandrine in cancer therapy. Acta Pharmacol Sin 2002;23:1102-1106.
138. Koukourakis MI, Bizakis JG, Skoulakis CE, et al. Combined irinotecan, docetaxel and conventionally fractionated radiotherapy in locally advanced head and neck cancer. A phase I dose escalation study. Anticancer Res 1999; 19: 2305-2309.
139. Choy H, MacRae R. Irinotecan and radiation in combined-modality therapy for solid tumors. Oncology (Huntingt) 2001 ;15:22-28.
140. Mitchell EP. Irinotecan in preoperative combined-modality therapy for locally advanced rectal cancer. Oncology (Huntingt) 2000;14:56-59.
141. Wachsberger P, Burd R, Dicker AP. R Improving tumor response to radiotherapy by targeting angiogenesis signaling pathways. Hematol Oncol Clin
North Am. 2004;18:1039-1057.
142. Dewhirst MW, Sim DA. Estimation of therapeutic gain in clinical trials involving hyperthermia and radiotherapy. Int J Hyperthermia. 1986;2:165-178.
143. Fowler JF. Eighth annual Juan del Regato lecture. Chemical modifiers of radiosensitivity theory and reality: a review. Int J Radiat Oncol Biol Phys.1985;11:665-674.